MedTrace Logo

Observational Study to Evaluate the Safety of Levemir® in Type 2 Diabetes

NCT00825643 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 18481

Last updated 2017-02-13

No results posted yet for this study

Summary

This study is conducted in Europe, North America and Asia. The aim of this observational study is to evaluate the safety and effectiveness while using Levemir® once daily in combination with oral antidiabetic drugs in type 2 diabetics during 24 weeks under normal clinical practice.

Data from the NN304-3573 study (NCT00740519) will be pooled with data from this study and reported together in the final study report for this study.

Conditions

Interventions

DRUG

insulin detemir

Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • Canada
  • China
  • Germany
  • Israel
  • Italy
  • Poland
  • Portugal
  • Spain
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00825643 on ClinicalTrials.gov